Why the validation signals that work in your ecosystem fail with foreign capital
Validation doesn’t travel. The proof you’ve built—credentials, grants, partnerships, traction—was calibrated within your home territory. Cross an ocean and the same evidence that made you a fundable venture at home, can make you look like a risk abroad.
This issue is about that gap.
Why Proof Standards Differ
The reason why proof doesn’t transfer easily is because individual capital markets, from the US to Singapore, often build their credibility markers around whoever first absorbed any early-stage risk. And this can differ significantly by region.
Consider the US, where private capital participates early. Angels and seed funds take pre-commercial risk before anyone else so naturally they developed their own filters, such as identified customers, signed pilots, reimbursement pathways for health-related ventures, or letters of intent. This commercial traction stack has become standard, in large part, because it allows private investors to evaluate deep tech ventures and spinouts without being experts on the science. Non-dilutive funding (eg. NIH, NSF, SBIR) can and does precede private investment in US deep tech, but it functions as a 1 to 2 year bridge rather than a substitute for equity rounds.
In Europe, there’s a different standard. In the case of spinouts, its often state-heavy. Major grant programs such as Horizon Europe, EIC, and national research councils generally assume the bulk of risk before private capital. Here, a scientific peer review becomes the main validation because the evaluators are scientists not investors; and commercial arguments are generally not required (or even discouraged) for longer period of time.
In Asia, industrial conglomerates and government-adjacent funds often take the lead, meaning that corporate partnerships, institutional affiliations and proximity to manufacturing ecosystems are at the forefront of validation and proof of concept.
Each ecosystem’s proof standard makes sense within its own ecosystem, which works fine if a founder wants to stay at home. But those who want to scale to other regions and markets face roadblocks. I’ve referenced these regional contexts in recent issues on Asia, MENA, and India, but here I’ll go further to illustrate a few cases that explain why this is happening and how founders can navigate these challenges.
Case 1 — EU to US: Immunocore
Immunocore is an Oxford University spinout that developed a TCR therapy platform that created an entirely new class of cancer treatment. The company’s science was unassailable: it had a novel mechanism, peer-reviewed validation, and deep institutional credibility within the European biotech sector.
The company spent over a decade building that proof. Early funding was predominantly European. The mechanism was novel but required years of scientific de-risking before US investors were willing to participate.
However, what eventually unlocked US capital wasn’t the mechanism but a clear clinical pathway. A specific indication (uveal melanoma), which was an FDA priority, led to the approval of KIMMTRAK in 2023 as the first-ever TCR therapy approved in the US. That sequence, from scientific proof to named US clinical anchor, is what made the proof transferable.
The lesson isn’t that European scientific validation is worthless in the US. It’s that it’s insufficient on its own. US investors needed a legible US-market proof point to unlock a decade of European scientific credibility, and that required early planning and strategy.
Case 2 — Asia to US: Preferred Networks
Preferred Networks is Japan’s most valuable AI company. Founded by researchers with ties to the University of Tokyo and deep relationships with Toyota, Fanuc, and NTT, it has raised over $3.7 billion and focuses on industrial AI and robotics.
Preferred’s capital base is almost entirely Japanese. Toyota is an anchor investor. Telecom giant NTT holds a significant stake; and government-adjacent funds have participated across multiple rounds. In Tokyo, a corporate partnership with a keiretsu anchor is the gold standard, which leads to follow-on investment from local institutions that further bolsters credibility.
That said, if Preferred is interested in the US market, a VC will read the company’s profile and ask: Where are the US customers or pilots? Which hyperscaler or enterprise buyer has a signed contract? What’s the dollar-denominated revenue? The Japanese corporate partnership, however large, only goes so far, and, in fact, may even raise more questions for the company operating in the US.
To date, Preferred Networks hasn’t made a significant push into the US market, and the proof gap helps explain why. The signals that make it fundable in Japan don’t answer the questions that a US fund would ask. Contrast this with Rebellions, the Korean AI chip company covered in Issue 24, which explicitly named US hyperscalers as buyers and priced the value proposition in cost-per-token terms against NVIDIA. They built a commercial thesis that US investors could verify independently, and raised over $400M from investors.
Case 3 — US to the EU: Autolus
Autolus is a UCL (University College London) spinout developing next-generation CAR-T cell therapies. It raised significant US capital, listed on Nasdaq in 2018, and spent years building toward FDA approval which it received in November 2024 (for Aucatzyl, a treatment for relapsed or refractory B-cell acute lymphoblastic leukemia).
What’s notable here is the sequence. The European Commission granted the company marketing authorization in July 2025, roughly eight months after the FDA approval. The US commercial proof came first; the European regulatory validation followed.
This is the US to EU dynamic in reverse. The company built its credibility case in US terms (named indication, FDA approval, US hospital launch, Nasdaq-listed financials) and that proof then unlocked the European pathway. European regulators still evaluated the science independently, but the US commercial anchor made this venture viable in Europe.
The inverse is also instructive. A US-originated spinout seeking EU grant funding before establishing US commercial proof runs into structural limits. This is because EIC Accelerator requires applicants to be established in an EU member state. Hence a US company with signed pilots and a confirmed reimbursement pathway cannot apply because its proof standard doesn’t fit with EIC’s program’s design.
The best practice for a US founder seeking EU capital or partnerships is to build European proof early, perhaps with a consortium partner, a university collaboration, or a regulatory pathway with a European agency. This may seem self-evident, but it requires early planning about where they are scaling globally and how to sequence it. That commercialization plan is not so obvious at the pre-commercial stage.
Summing Up
Immunocore had a decade to establish European scientific proof. Preferred Networks had institutional proof at the highest level of Japanese industry and government. Autolus built US commercial proof first and accessed European markets second. None of these ventures transferred its proof standard automatically. Each required deliberate planning.
The discipline is the same in every direction. Founders must know which evidence their target investors evaluate, and build proof points that answer their questions, not the question a local ecosystem might demand.
Whether it is about credentials, pilots or grants, a spin-out founder’s job is to build proof that travels. This only matters if you want it to travel, and at pre-commercial stage, many founders haven’t yet decided. The discipline is to build one proof point that travels before you need it to, even if you may not have decided yet.
One Action
List the three strongest proof points you would bring to an investor conversation outside your home market. Then ask yourself: which ecosystem built those signals, and what investors are actually going to evaluate them?
If the answer is within the same ecosystem, you have more work to do before you cross markets.
